Understanding how the epigenetic blueprint of the genome shapes human phenotypes requires systematic evaluation of the complex interplay between gene activity and the different layers of the epigenome. Utilizing microarray-based techniques, we explored the relationships between DNA methylation, DNA replication timing and gene expression levels across a variety of human tissues and cell lines. The analyses revealed unequal methylation levels among early-and late-replicating fractions of the genome: late-replicating DNA was hypomethylated compared with early-replicating DNA. Moreover, late-replicating regions were gradually demethylated with cell divisions, whereas the methylation of early-replicating regions was better maintained. As active genes concentrate at early-replicating regions, they are overall hypermethylated relative to inactive genes. Accordingly, we show that the previously reported positive correlation between gene-body methylation (methylation of the transcribed portion of genes) and gene expression is restricted to proliferative tissues and cell lines, whereas in tissues containing few proliferating cells, active and inactive genes have similar methylation levels. We further show that active gene bodies are hypermethylated not only compared with inactive gene bodies, but also compared with their flanking sequences. This specific hypermethylation of the active gene bodies is severely disrupted in cells of an immunodeficiency, centromeric region instability, facial anomalies (ICF) syndrome patient bearing mutated DNA methyltransferase 3B (DNMT3B). Our data show that a high methylation level is preferentially maintained in active gene bodies through independent cellular processes. Rather than serving as a distinctive mark between active and inactive genes, gene-body methylation appears to serve a vital, currently unknown function in active genes.
INTRODUCTION
DNA methylation plays an essential role in maintaining gene expression patterns through cell divisions. Approximately 10% of the 28 million CpG dinucleotide methylation sites in the human genome reside within gene promoters, in which they interact with other chromatin factors to facilitate gene silencing (1) . The role of the numerous other methylation sites located away from gene promoters, their interplay with other epigenetic marks and their association with gene expression phenotypes are still largely unknown.
Recent genomic analyses have shown that the transcribed portions of genes, commonly referred to as 'gene bodies', are hypermethylated compared with other fractions of the genome. Gene-body methylation profiles are conserved among vertebrates, invertebrates and plants, as well as the DNA methyltransferases generating and maintaining them (2 -4) . This suggests that gene-body methylation has an important function in multicellular organisms. According to the recent release of the human genome (assembly GRCh37/ hg19) and of the RefSeq gene database (build #43), more than a third of the human genome consists of gene bodies [see similar analysis in Table 11 of ref. (5)]. The occurrence of gene-body methylation in normal human tissues, the cellular mechanism responsible for its generation and its downstream effects remain unclear.
Genomic methylation has been frequently hypothesized to control cryptic transcription and transposition activity of foreign DNA elements. There is good evidence for such a role in plant species; however, the specific methylation enzymes involved in the repression of plant transposones are not conserved in mammals, in sharp contrast to the conservation of the enzymes involved in gene-body methylation (3, 4) . The evidence for methylation-based repression of transposones and of other repetitive elements in humans is controversial.
Intragenic methylation has also been hypothesized to influence gene expression levels by reducing the rate of transcription elongation (6, 7) . In this case, the methylation level should be negatively correlated with the gene expression level (i.e. higher methylation directs lower expression). Contrary to this expectation, we and others have demonstrated a positive correlation between gene-body methylation and gene activity in human cells (8) (9) (10) (11) , paralleling a similar association in plants (12) (13) (14) . This positive correlation (i.e. high methylation associates with high expression levels) contradicts the traditional perception of DNA methylation as a marker of inactive chromatin. The cellular mechanism responsible for the link between gene-body methylation and gene activity remains unclear.
DNA methylation is unique among the different layers of epigenetic marks due to its established role in the somatic inheritance of epigenetic states from mother to daughter cells (1) . DNA methylation patterns are established during embryogenesis by the de novo DNA methyltransferases 3a and 3b (DNMT3A, DNMT3B). They are maintained through successive cell divisions by the DNA methyltransferase 1 (DNMT1), which catalyzes the replication of methylation patterns from template to newly synthesized DNA strands following DNA replication (15) . In the absence of maintenance activity, methylation marks are gradually erased through cell divisions, a process referred to as 'passive demethylation' (as opposed to active removal of methyl marks by demethylation factors).
Another epigenetic blueprint that may play an instructive role in somatic inheritance is replication timing (16) . DNA replication during the first half of the S phase (early replication timing) promotes an open chromatin state and facilitates transcription. Accordingly, late replication timing leads to a closed chromatin state and to gene silencing (17) . Thus, replication timing may facilitate the reconstruction of active and inactive chromatin regions following cell division. In agreement with this model, genes that reside in early-replicating genomic regions are more likely to be active than genes in late-replicating regions (18 -20) . However, genomic analyses showed that both early and late replication timing zones often harbor both active and inactive genes. Moreover, replication timing seems to be connected with the composition of the DNA sequence and with the density of genes more strongly than with the level or with the probability of gene expression (19 -22) . Thus, the causative relationships between replication timing and gene expression remain unclear.
In addition to their role in establishing de novo methylation patterns, DNMT3A and DNMT3B may also participate in maintaining methylation, either directly or through the proofreading of DNTM1 activity (23) . Mutations in DNMT3B lead to the immunodeficiency, centromeric region instability, facial anomalies (ICF) syndrome (24, 25) . ICF cells demonstrate a moderate decrease in overall genomic methylation compared with normal cells. They also show more significant hypomethylation of particular satellite and non-satellite repeat sequences (26, 27) , which may correspond to the repertoire of chromosomal instabilities typical of these cells. Yet, the causal relationships between DNMT3B mutation, methylation abnormalities and the range of ICF phenotypes remain obscure.
Here, we explore interactions between replication timing, DNA methylation and gene expression across the genome. We show a strong connection between early replication timing and high levels of DNA methylation. This connection facilitates high methylation of early-replicating genes. In addition, a gene-specific mechanism further ensures high methylation levels at active genes, regardless of their replication timing. The combined actions of these two independent mechanisms provide superior maintenance of high DNA methylation levels along active gene bodies. Inactive gene bodies, however, tend to lose methylation through cell divisions. We find that this superior maintenance of methylation of the active gene bodies is severely disrupted in ICF cells, indicating the importance of de novo methyltransferases in this process.
RESULTS

Microarray-based assessments of DNA methylation and DNA replication timing
We sought to explore the roles of the numerous methylation sites located away from gene promoters, their interaction with other epigenetic marks and their association with gene activity. We also wished to explore the occurrence of gene-body methylation in normal human tissues, the cellular mechanism responsible for its generation and the effects of abnormal gene-body methylation on human phenotypes.
To do this we modified our established microarray-based methylation assay (8) to allow sensitive quantification of methylation levels at up to 927 151 genomic fragments encompassing 2 322 647 assessable CpG dinucleotides ( 8.3% of human CpGs). This assay uses the ratio between hybridization intensities of DNA samples before and after digestion with a cocktail of five methyl-sensitive restriction enzymes (MSREs) to generate quantitative methylation scores (Fig. 1A) . Accuracy and reproducibility of the assay were verified through quantitative bisulfite sequencing of representative CpG sites (Supplementary Material, Fig. S1A and B) and through the comparison of our results with similar analyses performed by others (Supplementary Material, Fig. S1C ) (28) .
To explore connections between DNA methylation and replication timing, we generated a genome-wide map of replication timing in B lymphocytes (Fig. 1B) , utilizing an established microarray-based replication timing assay (19) (20) (21) (22) 29, 30) . In this assay, the ratio between the S phase and the G 1 copy numbers is simultaneously assessed for numerous genomic loci in large populations of unsynchronized cells. This ratio is directly related to the time of replication, since the S phase copy number of any given locus is a function of the fraction of cells in which this particular locus has already replicated, and the fraction of cells in which this particular locus has not yet replicated (20) . One advantage of this assay over earlier replication timing methods is that cell synchronization and precise fractionations of the S phase are not required. Utilizing this assay we confirmed genome-wide associations of replication timing with GC content and gene density (Supplementary Material, Fig. S2B and C) , as previously described (19, 20) . The chromosomal replication timing profiles we obtained (Supplementary Material, Figs S2A and S3) agree well with similar analyses performed by others (19, 30) .
Genome-wide association between DNA methylation and replication timing Utilizing our microarray-based assays, we revealed a close association between DNA methylation and replication timing. Early replication timing was correlated with high DNA methylation throughout the genome (R ¼ 0.608) ( Fig. 2A) , as well as within gene bodies (Fig. 2B) or along distinct chromosomes ( Fig. 2D and Supplementary Material, Fig. S4D ). However, the correlations of DNA methylation with gene density and with GC content were considerably weaker ( Fig. 2E and Supplementary Material, Fig. S4E ), suggesting that the connection between DNA methylation and replication timing is not secondary to the connection of replication timing with GC content and with gene density.
Enhanced demethylation at late-replicating regions
Using the NHF primary cells, we next explored the rate of demethylation during ongoing cell divisions. As expected, overall genomic methylation levels gradually decreased through increasing population doublings (PDs) (Supplementary Material, Fig. S6 ). However, the rate of methylation loss was higher in late replicating genomic regions (Supplementary Material, Fig. S6 ), leading to enhanced hypomethylation of late-replicating sequences in later PDs. Therefore, the methylation differences between early-and late-replicating DNAs seen in Figure 2 are not constant, but develop with the accumulation of cell divisions.
Methylation -expression relationships in normal human tissues
We next explored the incidence of gene-body methylation in normal human tissues. We also sought to elucidate the mechanism underlying the reported positive correlation between gene-body methylation and gene expression. Former studies focused on immortalized human cell lines (9, 11) . Confirming these reports, our data showed positive correlations between gene-body methylation levels and gene expression levels in Blymphocyte cell lines ( Fig. 3 and Table 1 ). We also revealed positive correlations in placenta, in freshly obtained peripheral Figure 1 . Microarray-based assessments of DNA methylation and DNA replication timing. (A) For methylation assessments, genomic DNA samples were treated with a cocktail of five methyl-sensitive restriction enzymes (MSREs), leading to digestion of unmethylated MSRE sites (I), while methylated sites remained intact. Treated and untreated DNAs were then PCR amplified from universal primers (arrowheads), and the resulting amplicons containing the MSRE sites (II) were labeled and hybridized to mapping microarrays (III). This procedure led to a smaller amount of PCR product and consequently to reduced hybridization intensities of amplicons enclosing unmethylated MSRE sites, compared with that of untreated DNA. The relative hybridization intensities of six probe sets are shown for a representative amplicon (IV). The ratio between the hybridization intensities of untreated and MSRE-treated sites was then used to generate a quantitative methylation score (V), which was closely related to the methylation level measured by pyrosequencing (Supplementary Material, Figure S1 ). (B) For replication timing, cells were harvested from exponentially growing cultures, fixed and sorted into distinct phases of the cell cycle according to DNA content (I). Genomic DNAs were extracted from 1 × 10 6 cells of G 1 and early S phases and hybridized to microarrays in duplicate (II). Hybridization intensity outputs were then normalized (III) and copy number was evaluated in G 1 and early S phases (IV) for each of the arrayed genomic loci. Replication timing scores were expressed as the log 2 of the ratio between the DNA copy number in the early S and the DNA copy number in the G1 phase (V). This ratio is directly related to replication timing, as the fraction of cells in which a given locus was already replicated (in populations of unsynchronized cells) and the fraction of cell in which this locus was not yet replicated corresponds to the replication timing of this particular locus (20) .
white blood cells (WBCs) and in normal fibroblasts ( Fig. 3 and Table 1 ). Thus, high levels of gene expression were associated with high levels of gene-body methylation in normal human tissues. We also examined tissue-specific genes in expressing and non-expressing tissues. These genes were methylated in the expressing tissues but not in the tissue in which they were not expressed (Supplementary Material, Fig. S7 ). These analyses further confirmed the positive correlation between gene-body methylation and gene expression, as opposed to the negative correlation found in gene promoters.
However, our analysis also showed that a positive correlation between gene-body methylation and gene expression is not a general characteristic of human cells. Instead, the examination of a range of tissues and cell lines yielded two general observations: first, active gene bodies demonstrated a very high (almost complete) methylation level across all tissues and cell types (dashed blue lines in Fig. 3A -E) . Secondly, inactive genes were hypomethylated (compared with the active genes) in proliferative tissues, including WBCs, fibroblasts and placenta, but not in slowly dividing tissues such as the kidney and lung. An extreme situation was observed in the brain (either whole brain or occipital lobe): in this tissue, the inactive and low expressed genes were methylated at higher levels than the highly expressed genes ( Fig. 3E and Table 1 ). Thus, hypomethylation of inactive genes appears to be associated with a proliferative cellular state.
Utilizing the NHF cells, we compared the methylation levels of active and inactive genes during ongoing cell divisions. We found that while active genes maintained a constantly high methylation level over increasing PDs, the methylation of inactive genes gradually decreased in progressive PDs (Fig. 3F and Table 1 ). Taken together, these results suggest that inactive genes are more prone to lose gene-body methylation marks during cell divisions. This process would lead to the observed positive correlation between methylation and gene expression seen preferentially in proliferative cells.
Replication timing-related and replication timing-independent gene-body methylation
We next sought to explore why inactive genes tend to lose more methylation during cell divisions than active genes. One possibility is that the enhanced demethylation at late-replicating regions (Supplementary Material, Fig. S6 ) has a greater effect on inactive genes than on active genes. As inactive genes tend to occupy late-replicating regions (16) , which are generally hypomethylated (Fig. 2) , they may adopt the hypomethylated state of their surroundings. Alternatively, genes may sustain intrinsic methylation levels, regardless of the methylation level of the genomic regions in which they are embedded.
To distinguish between these possibilities, we tested whether gene-body methylation was more closely related to the intrinsic expression level of genes or to the replication timing of their genomic environment. Figure 4A shows the methylation levels of all genes assigned into six bins representing increasing expression levels. Each of these is subdivided into six replication timing bins, each representing a different replication time point. If the differences in methylation levels between expressed and non-expressed genes were merely secondary to the different replication timing of these gene bins, then methylation differences should appear between replication timing bins within each expression bin but should be equal in genes in the same replication timing across different expression bins. This model is illustrated in Figure 4B -I. Conversely, if the differences in methylation between early-and late-replicating genes were secondary to their different expression levels, then methylation differences should be seen only between expression bins but not between replication timing bins within a given expression bin. This possibility is shown in Figure 4B -II. However, the actual results fit a third model, showing methylation differences both within and between expression bins ( Fig. 4A and B-III) . Thus, gene-body methylation is independently linked to both replication timing and gene activity.
To better understand this connection of DNA methylation to both replication timing and gene expression levels, we examined replication timing and DNA methylation across gene bodies and flanking sequences. We analyzed whether the gene-body methylation level was more closely related to the intrinsic expression level of genes or to the replication timing of flanking sequences. Gene-body boundaries (i.e. transcription start and stop sites) and replication timing boundaries (i.e. transition sites between early and late replication time zones) are rarely co-localized, as replication time zones are typically much longer than individual genes (20) . Accordingly, we found similar replication timing in genes and at their adjacent sequences, upstream and downstream of genes (Fig. 4C) . Despite this similar replication timing at genes and their flanking sequences, the analysis of gene-body methylation and of surrounding sequences showed that active genes were hypermethylated not only compared with inactive genes, but also compared with their flanking sequences ( Fig. 4D and Supplementary Material, Fig. S10 ). This indicates that gene-body methylation is not only associated with regional replication timing, but also with the intrinsic expression level of genes. It must therefore be concluded that increased methylation of active gene bodies cannot be achieved solely by a mechanism associated with DNA replication, since such a mechanism must produce equal methylation along genes and surrounding sequences. Thus, there must be a different mechanism, potentially linked to gene transcription, which targets active genes in early-as well as in late-replicating regions and generates gene-body-specific methylation in addition to the methylation associated with early replication timing. Due to this gene-specific mechanism, the correlation between replication timing and methylation in gene bodies is weaker than in non-genic sequences (Fig. 4E -F and Supplementary Material, Fig. S8 ).
Aberrant gene-body methylation in ICF
The only known human pathology exhibiting Mendelian inheritance of aberrant DNA methylation is the ICF syndrome (24, 25) . This syndrome results from mutations in the de novo DNMT3B methyltransferase gene. Genomic analyses of lymphocyte cell lines established from ICF patients revealed slightly decreased overall genomic methylation and more significant hypomethylation of particular satellite and non-satellite repeats (26, 27) . However, the causal relationships between DNMT3B mutation and the disease phenotypes remain unclear.
We examined methylation of Epstein -Barr virus (EBV) transformed lymphocytes from an ICF patient carrying a mutated DNMT3B, and compared them with the methylation of unaffected EBV-transformed lymphocytes. In agreement with the previous reports, we observed slightly decreased overall genomic methylation: the overall genomic average methylation score of the ICF cells was 0.87, compared with an average methylation score of 0.95 in the unaffected cells (0.08 methylation score difference). However, we found that the difference between the methylation levels of the ICF cells and the unaffected cells was larger in active gene bodies than in inactive gene bodies. The methylation of the active gene bodies was 0.16 methylation score lower than the methylation of active gene bodies in the unaffected cells, 2-fold larger than that overall methylation reduction. Conversely, the effect on inactive gene bodies was smaller than the overall effect (0.06 methylation score difference). Moreover, in the ICF cells, the methylation level of the active gene bodies was significantly lower than the methylation level of the active gene bodies in all other examined tissues and cell lines (Fig. 5A) . Across all the examined tissues and cell types, only the ICF cells showed incomplete methylation of active gene bodies. Inactive gene bodies also showed reduced methylation in the ICF compared with unaffected cells (Fig. 5B ), but in contrast to the active genes this reduction was in agreement with the overall genomic methylation reduction and also with the normal range of inactive genebody methylation over different cell types. Strikingly, the specific hypermethylation of active gene bodies compared with flanking sequences, described above, was completely abolished in the ICF patient-derived cells (Fig. 5C ). We conclude that gene-body methylation of active genes is dramatically altered in the ICF cells, contrasting with the milder effect on inactive genes or on the genome as a whole. The analysis showed that the correlation between replication timing and DNA methylation is weaker within gene bodies, presumably due to the effect of the gene-specific, replication timing-independent mechanism. (F) Genome-wide correlations of methylation with replication timing, with GC content and correlation of GC content with replication timing in 1 Mb windows along the genome. The analysis showed that methylation to replication timing, but not the other correlations, is weaker within gene bodies.
DISCUSSION
The origin of expression-related gene-body methylation
Positive correlations between gene-body methylation and gene expression were previously described in the flowering plant Arabidopsis thaliana (12), in a variety of human cell lines (8, 9, 11) and in primary human CD19 + B cells (10). Here we further establish this phenomenon in lymphocytes, in the placenta and in cultured normal foreskin fibroblasts (Fig. 3) . Thus, expression-related gene-body methylation is not limited to artificially transformed cell lines. However, it is also not a universal feature of the human body, since other tissues including the lung, kidney and the brain do not exhibit this phenomenon (Fig. 3) . Instead, our data reveal the efficient maintenance of high methylation levels along active gene bodies as a general characteristic of all examined tissues and cell lines, with the clear exception of the ICF patient-derived cells (Fig. 5) . In contrast, the methylation level of inactive gene bodies appears to be a tissue-specific trait, being high in the lung, kidney and brain but low in placenta, fibroblasts and lymphocytes.
DNA demethylation can occur through active removing of methyl residues by demethylation enzymes, or by passive loss of methylation marks through cell divisions due to incomplete replication of the methylation pattern from template to newly replicated DNA strands. Active demethylation occurs genome-widely during early development stages, and possibly at specific loci in somatic tissues (31) . On the other hand, passive demethylation due to inefficient methylation maintenance is a well-established phenomenon that occurs genomewidely (15) . Although our data do not exclude active demethylation, the global, gradual demethylation, we observed through accumulated divisions of somatic proliferating cells (Fig. 3) fits with a passive demethylation mechanism.
Differential rates of demethylation through accumulating cell division
Our data suggest that tissue-specific gene-body methylation reflects the different cell division history of rapidly versus slowly dividing cells and is due to the differential rates of demethylation in late-versus early-replicating genomic regions and in active versus inactive gene bodies (Figs 2 and 3) .
One prediction of this model is that active and inactive genes are equally methylated during early development stages. A recent analysis of gene-body methylation in H1 embryonic stem cells (11) confirms this expectation. Interestingly, in two brain samples taken from different individuals, the most highly expressed genes were hypomethylated compared with all other genes ( Fig. 3E and Table 1 ). This may signify a methylation pattern unique to the brain.
We discovered a strong correlation between replication timing and DNA methylation across the genome, in developmentally distant cell lineages, such as lymphocytes (Fig. 2) and fibroblasts (Supplementary Material, Fig. S4 ), suggesting that the connection between early replication timing and high gene-body methylation is a phenomenon shared by many cell types in the human body. The mechanism underlying this connection appears to be accelerated demethylation in late-replicating DNA (Supplementary Material, Fig. S6 ), which results in hypomethylation of the late-replicating regions following accumulated cell divisions. It remains to be tested whether differential expression of methyltransferases (32) and/or differential availability of the methyl donors throughout the cell cycle underlie this differential rate of demethylation in early-and late-replicating regions.
Despite extensive study, the mechanisms that link replication timing and gene expression have not been clarified, and the role of the genomic partitioning into early and late replication time zones remains unknown. On the basis of our results we suggest that localization of active genes in early replication time zones allows efficient maintenance of methylation where it is apparently required (i.e. in active gene bodies), while reducing the cost of methylation maintenance at the inactive portion of the genome where a precise methylation level is presumably not essential.
The source of the specific methylation of gene bodies
At the local and regional scales, factors such as the local level of chromatin condensation, position-effect variegation, allelespecific methylation, etc., might have a greater effect on the level of gene-body methylation than replication timing or gene expression level. However, our data clearly show that overall in the genome, the two most significant factors connected with methylation levels are replication timing and gene expression. Moreover, replication timing showed a tighter connection with the methylation level in intergenic regions ( Fig. 4E and F) , whereas gene expression levels showed a tighter connection with the methylation of gene bodies (Fig. 4D) .
Although active genes are more frequent in early-replicating regions than in late-replicating regions, the correlation between replication timing and gene expression levels is not complete (Supplementary Material, Fig. S9 ). Thus, a significant number of active genes reside in late-replicating regions (19) (20) (21) . The gene-specific mechanism we observed is able to specifically target such genes for methylation, and to avoid methylation of inactive genes and non-genic sequences. Thus, this mechanism must possess information on both the location and the activity level of genes. A probable mechanism for this genome-wide effect is transcription-coupled methyltransferase activity. We showed that gene-specific methylation is abolished in cells with a mutated DNMT3B gene (Fig. 5) . Thus, DNMT3B may act as a transcription-coupled methyltransferase in somatic cells, in addition to its role as a de novo methyltransferase during embryogenesis. Given its limited expression level in somatic cells (15) , coupling with the transcription machinery may focus its activity at particularly important targets.
The significance of gene-body methylation
We show that active gene methylation is maintained through cooperation between a set of mechanisms: a regional, replication timing-related mechanism and a gene-specific mechanism (Fig 4) . The use of multiple mechanisms that ensure high DNA methylation at active gene bodies indicates that an important cellular process is mediated through gene-body methylation. The significant conservation of gene-body methylation among distant phyla (2 -4) further supports it having an essential function. This unknown function is clearly not the distinction of active from inactive genes, since, in some tissues, active and inactive gene bodies share similar methylation levels (Fig 3) . It is possible that transcriptionally active regions are particularly susceptible to deleterious processes such as initiation of improper transcription and/or chromosomal aberrations (33) and are thus specifically protected through gene-body methylation. Other possible functions are the regulation of transcription elongation rates (7) or the control of alternative promoter usage (34, 35) .
Cells derived from ICF patients were the only example of incomplete gene-body methylation in active genes (Fig. 5) . Moreover, in these cells, active genes suffer more methylation reduction than inactive genes or than the entire genome, and the gene-specific methylation mechanism is severely disrupted (Fig. 5) . Extended study of the interplay between gene-body methylation and somatic DNMT3B activity may shed light on the role of gene-body methylation in normal tissues as well as in pathogenic states.
MATERIALS AND METHODS
Ethics statement
Human participants were approved by the Hadassah Medical Center Review Committee according to the principles of the Declaration of Helsinki. All data were analyzed anonymously. 
High throughput methylation assay
One microgram of genomic DNA was digested at 378C for 16 h with an MSRE cocktail, including AciI (20 U), BsaHI (1.3 U), HhaI (2.5 U), HpaII (2.5 U) and HpyCH4IV (10 U) (NewEngland Biolabs), in a 50 ml reaction volume with 0.1 mg/ml BSA and 10% NEB buffer #4 (New England Biolabs), ethanol precipitated and resuspended in Tris-EDTA buffer at 50 ng/ml. After this pre-treatment, a hybridization procedure was followed according to the manufacturer's instructions (www.Affymetrix.com). Affymetrix 6.0 microarrays were utilized in the analysis of B-lymphocyte lines and the occipital lobe. All other tissues and lines were analyzed by Affymetrix Nsp250K microarrays. Hybridization intensities (average of both alleles for each of the amplicons) before and after MSRE treatment were normalized using the dChip software package (www.dchip.org), applying an invariant set of amplicons without MSRE sites (which are insensitive to MSRE treatment). Methylation scores were expressed as 1 2 log 2 of the hybridization intensities before/after MSRE treatment. To eliminate possible errors due to inter-individual sequence polymorphism, amplicons with known polymorphisms (SNP db build #129) in any of the five MSREs or in the NspI or the StyI sites were omitted from the analysis. The remaining 927 151 informative amplicons encompassing 2 322 647 CpGs in assessable MSRE sites (348 585 CpGs in 136 360 amplicons in the NspI 250K microarray) were used in the analyses.
Verification of methylation through quantitative bisulfite sequencing
Eleven representative MSRE sites were PCR amplified from a bisulfite-converted DNA pool (Qiagen EpiTect kit) consisting of 68 WBC genomes, and sequenced on a Q24 pyromark sequencer according to the manufacturer's instructions (www.qiagen.com).
Replication timing
EBV-transformed female B-lymphocyte cell lines GM12092 and GM12093 were cultured as above, harvested from logarithmic growth cultures, washed once in ice-cold phosphatebuffered saline, immediately fixed in 70-85 -95% ethanol at 2208C, stained with propidium iodide and sorted using an MoFlo cell sorter. Genomic DNA samples were purified from G 1 and from the first half of the S-phases (Fig. 1B) and hybridized to Affymetrix StyI 250K arrays. G 1 and early S copy numbers (both alleles of each amplicon) were analyzed by dChip software package (www.dchip.org).
Analysis of gene-body methylation
A total of 13 728 genes with at least one informative amplicon probe were identified using the RefSeq Genes database, release #34 (www.ncbi.nlm.nih.gov/RefSeq). An informative amplicon probe was defined as an NspI-NspI, StyI-StyI or NspIStyI amplicon with at least one probe on the Affymetrix 6.0 mapping array, at least one MSRE site recognized by our enzyme cocktail and no known polymorphism (SNP db build #129) in any of the enzyme recognition sites. Relative positions [the distance from the transcription start site (TxS) divided by the gene size] were assigned to each of the informative amplicons, and the median methylation scores were evaluated in sliding windows of 10% of the gene size and in 0.5% steps along gene bodies, or in sliding windows of 1 kb, 95% overlapping upstream and downstream of genes, or in sliding windows of 1 Mb, 90% overlapping along the genome. Figure S11 . For the correlation with gene expression, all informative genes were divided into six expression bins according to published data (37) for the examined tissues. ICF expression data were according to the GEO datasets accession GSE9499 (www.ncbi.nlm.nih.gov/geo).
Data analysis
Linear Pearson's correlation was used for all correlations. Differences between distributions were analyzed by the K -S test. Computer simulations were performed by arbitrarily shuffling the data 10 000 times, re-assigning it into expression level or replication timing bins and analyzing the differences between the new bins. The presented P values are the frequency of permutations with the same or greater differences than the actual data.
Data deposition
Raw microarray hybridization outputs and DNA methylation and DNA replication timing signals have been deposited in the GEO database (www.ncbi.nlm.nih.gov/geo), accession # GSE24947.
